Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — Q1 FY2019 Earnings Presentation
21 slides from Thyrocare Technologies's earnings presentation, Aug 13, 2018
Slide 1: Thyrocare cover letter to stock exchanges
Thyrocare’ Think Thyroid. Think Thyrocare. August 13, 2018 The National Stock Exchange of India Limited The Bombay Stock Exchange Ltd Exchange Plaza 2 Phiroze Jeejecboy Towers Bandra Kurla Complex, = Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 Dear Sirs, Sub: Presentation on Quarterly
Slide 2: Thyrocare Technologies Limited Q1-FY19 Presentation
Thyrocare Technologies Limited Q1-FY19 Presentation August 11, 2018
Slide 3: Disclaimer
Disclaimer • This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informat
Slide 4: Consolidated Financials Q1-FY19 Highlights
Consolidated Financials Q1-FY19 Highlights
Slide 5: Key Highlights – Q1-FY19
Key Highlights – Q1-FY19 • Consolidated Quarter Performance: • Consolidated Profit Before Tax of ₹ 37.6 Crore, ▲ 9% • Consolidated EBITDA Of ₹ 41.2 Crores, ▲ 13% • Consolidated Revenue Of ₹ 97.2 Crores, ▲ 11% Thyrocare Standalone: • Profit Before Tax of ₹ 38.9 Crores, ▲ 9% • EBITDA Of ₹ 39.2 Crores,
Slide 6: Consolidated Financials
Consolidated Financials Thyrocare Technologies Limited [Consolidated] Thyrocare Technologies Limited [Consolidated] P&L Statement (INR Cr., except for Per Share Data) Balance sheet data (INR Cr., except for Per Share Data) Particulars Quarter Ending YoY Growth Financial Year Ending YoY Growth Partic
Slide 7: Thyrocare Standalone
Thyrocare Standalone Thyrocare’ ‘Think Thyroid. Think Thyrocare
Slide 8: Standalone Financials - Thyrocare
Standalone Financials - Thyrocare Thyrocare Technologies Limited [Standalone] Thyrocare Technologies Limited [Standalone] P&L Statement (INR Cr., except for Per Share Data) Balance sheet data (INR Cr., except for Per Share Data) Particulars Quarter Ending YoY Growth Financial Year Ending YoY Growth
Slide 9: Commentary on Financials - Thyrocare
Commentary on Financials - Thyrocare • Revenue from operations QoQY ▲ 9% inspite of price rationalization - mainly on account of growth in B2B segment. • Revenue from preventive care tests, profiles & packages constitutes 53% of the revenue from diagnostic services. • COGS as % of revenue from opera
Slide 10: Key Financial Trends - Thyrocare
Key Financial Trends - Thyrocare Revenue (INR Cr) 90.0 89.2 82.4 82.1 81.8 77.8 73.4 64.5 65.7 Q1-FY17 Q2-FY17 Q3-FY17 Q4-FY17 Q1-FY18 Q2-FY18 Q3-FY18 Q4-FY18 Q1-FY19 45.0 EBITDA (Cr) 100% 39.2 40.0 35.8 33.9 34.5 35.3 90% 31.2 80% 29.9 35.0 26.1 70% 30.0 26.0 60% 25.0 50% 20.0 40% 15.0 41% 41% 44%
Slide 11: Samples and Investigations
Samples and Investigations # Samples (‘000 Samples) # Investigations (‘000 investigations) 5.3 30000 5.5 5.2 5.1 5.1 5.1 4,580.1 5 25000 23,059.7 23,424.4 20,749.1 20,751.1 4,355.1 4.5 20000 19,710.0 4 4,082.4 15000 4,017.7 3.5 3,873.2 10000 3 5000 2.5 0 2 Q1-FY18 Q2-FY18 Q3-FY18 Q4-FY18 Q1-FY19 Q1-
Slide 12: Key Operating Metrics – Business Lines
Key Operating Metrics – Business Lines Revenue Breakup (INR Cr) Volume Breakup (‘000 Samples) Q1-FY19 14.6 29.5 3.0 36.7 Q1-FY19 112.1 444.0 263.7 3,760.2 Q4-FY18 15.8 25.2 1.6 40.9 Q4-FY18 124.8 392.1 231.3 3,606.9 Q3-FY18 12.9 21.0 1.4 37.1 Q3-FY18 99.9 328.0 185.9 3,259.4 Q2-FY18 16.7 23.8 1.7 34
Slide 13: Key Operating Metrics – Regional Breakup
Key Operating Metrics – Regional Breakup Value Breakup (INR Cr) Volume Breakup (Lakh Samples) Q1-FY19 19.0 21.1 26.3 16.6 0.7 Q1FY19 10.0 12.5 11.6 11.6 0.1 Q4-FY18 13.4 20.1 27.7 14.2 4.4 Q4-FY18 9.4 12.9 9.8 10.2 1.2 Q3-FY18 13.1 18.3 26.6 12.5 1.9 Q3-FY18 7.2 11.9 8.3 9.1 2.2 Q2-FY18 22.6 19.7 20
Slide 14: Operating Data
Operating Data Thyrocare Technologies Limited Particulars Quarter Ending Yo Y Growth Financial Year Ending Yo Y Growth June 30, 2018 June 30, 2017 March 31, 2018 March 31, 2017 B2B revenue (in crore) 66.17 55.44 19% 237.55 200.56 18% B2C revenue (in crore) 17.59 20.70 -15% 70.73 62.67 13% B2B revenu
Slide 15: Nueclear Standalone
Nueclear Standalone Nue@clear
Slide 16: Standalone Financials - Nueclear
Standalone Financials - Nueclear Nueclear Healthcare Limited [Standalone] Nueclear Healthcare Limited [Standalone] P&L Statement (INR Cr., except for Per Share Data) Balance sheet data (INR Cr., except for Per Share Data) Particulars Quarter Ending YoY Growth Financial Year Ending YoY Growth Particu
Slide 17: Key Highlights – Nueclear – Q1-FY19
Key Highlights – Nueclear – Q1-FY19 • Nueclear has completed 80,000 scans as of August 2, 2018 • Our New Center in Nasik commenced operations in July 2018, taking the total to 10 centers across India. • Revenue from operations grew by 42% to INR 7.96 Crores • Driven by stellar performance of new cen
Slide 18: Key Financial Trends - Nueclear
Key Financial Trends - Nueclear Revenue (INR Lakhs) 796.0 662.3 625.0 603.2 561.7 474.2 468.4 475.5 422.8 Q1-FY17 Q2-FY17 Q3-FY17 Q4-FY17 Q1-FY18 Q2-FY18 Q3-FY18 Q4-FY18 Q1-FY19 200.0 50% 179.2 180.0 EBITDA (INR Lakhs) 156.4 45% 154.1 140.0 160.0 40% 140.0 35% 120.0 25% 23% 24% 30% 100.0 23% 25% 80.
Slide 19: Centerwise Scan Volumes
Centerwise Scan Volumes* Centerwise Scan Volumes 18 100% 49 158 320 199 304 95 307 356 580 471 440 638 538 90% 611 436 579 208 689 548 474 80% 659 1421 725 681 70% 738 808 253 295 2,339 60% 847 830 1,972 1,766 2,090 50% 1,839 1,646 1080 40% 1,647 30% 1575 20% 1,889 1,717 1,741 1,967 1,837 1,750 1,84
Slide 20: Centerwise Scan Revenues
Centerwise Scan Revenues Centerwise Scan Revenues (INR Lakhs) 1.9 100% 8.0 10.0 28.0 31.8 15.0 31.3 48.0 48.3 57.0 56.0 32.0 33.0 53.6 90% 9.5 70.0 31.4 30.9 57.0 82.0 116.1 80% 65.8 64.0 81.6 71.0 70% 38.3 76.0 22.6 82.9 191.0 83.8 60% 99.6 160.0 148.0 50% 184.0 186.0 162.4 105.0 156.1 40% 30% 147.
Slide 21: Thank You
Thank You O Think Thyroid. Think Thyrocare. Nuclear NATIONWIDE NETWORKED
Thyrocare Technologies — Q1 FY2019 Earnings Presentation on 6ix